Scientists test new 'Tumor-Seeking' radiation in early cancer trial
NCT ID NCT06148636
Summary
This is a very early safety study to find a safe dose of a new radioactive drug, [212Pb] VMT-alpha-NET, for people with advanced neuroendocrine tumors that have stopped responding to other treatments. The main goal is to see how much radiation the kidneys can safely handle during treatment. Participants receive two infusions of the drug, several weeks apart, and are closely monitored for side effects for at least six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Holden Comprehensive Cancer Center at the University of Iowa
Iowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.